Skip to content

Using Nanotechnology Structured Water to Control Blood Glucose in Type 2 Diabetic Patients.

Evaluation of Using a Nanotechnology Structured Water Magnalife® to Achieve Controlled Blood Glucose Level in Type 2 Diabetic Patients.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04082351
Enrollment
387
Registered
2019-09-09
Start date
2016-07-03
Completion date
2018-02-16
Last updated
2019-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 Diabetes

Keywords

Nanotechnology water, HbA1c, Type 2 Diabetes mellitus

Brief summary

Type 2 DM is due to insulin resistance or low insulin secretion or sometimes a combination of both. Nanotechnology structured water is a type of water that is produced using energy field modulators to change the biological, chemical, and physical properties of water molecules and improve the bioavailability of this nano-water. Objective: To find out the effect of drinking nanotechnology structured water (Magnalife®) on the blood glucose levels in patients with type 2 diabetes mellitus.

Detailed description

This is a blind randomized control trial, according to CONSORT guidelines for randomization, Participants were randomly assigned following simple randomization procedures (computerized random numbers) to 1 of 2 treatment groups., that included 387 patients with Type 2 diabetes mellitus in Diabetes Care Center, Sulaymaniyah, Kurdistan region from July 2016 till February 2018. A total of 387 patients with type 2 diabetes who were patients in this center and agreed to participate in this clinical trial were included in this study. In group A, patients were given nanotechnology structured water Magnalife® and in group B they were given ordinary bottled drinking water as a control . The bottles were unlabeled so that the patients did not know which water they were drinking. Then they were asked to eat their usual food and to drink their usual drinks, also they could drink water ad libitum after drinking the daily doses, and to have the same physical activities that they used to do in their usual daily life. They were instructed to take their medications as usual, and were told to come to test their blood sugar level at the end of the third month to get the HbA1c tested at the end of the three months of drinking the water.

Interventions

DIETARY_SUPPLEMENTNanotechnology structured water ( Magnalife)

Nanotechnology structured water ( Magnalife), is given as dietary supplement to the patients to drink it according to their weight .

DIETARY_SUPPLEMENTordinary water

Ordinary bottled water

Sponsors

ALI KAMAL M. SAMI
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Type 2 diabetic patients

Exclusion criteria

* Malignancy * Steroids * Immunotherapy * Chemotherapy * Radiotherapy * Chronic infections * Drugs that antagonize or synergies insulin effects

Design outcomes

Primary

MeasureTime frameDescription
HbA1cthree monthsmeasurement of HbA1c

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026